

India Minimally Invasive Biopsy Techniques Market Assessment, By Product Offered [Tests, Kits & Consumables, Instruments], By Technique [Liquid Biopsy, Optical Biopsy, Brush Biopsy, Pigmented Lesion Assays, Others], By Circulating Biomarker [Circulating Tumor Cells, Cell Free DNA, Circulating Tumor DNA, Extracellular Vesicles, Others], By Application [Clinical, Therapeutic], By End-user [Hospitals & Clinics, Academic & Research Institutions, Ambulatory Care Centers], By Region, Opportunities and Forecast, FY2017-FY2031F

<https://marketpublishers.com/r/IE6A30706E8CEN.html>

Date: March 2025

Pages: 102

Price: US\$ 3,300.00 (Single User License)

ID: IE6A30706E8CEN

Abstracts

India minimally invasive biopsy techniques market size was valued at USD 194.5 million in FY2023, which is expected to reach USD 423 million in FY2031, with a CAGR of 10.2% for the forecast period between FY2024 and FY2031. India minimally invasive biopsy techniques market has witnessed significant growth due to its ability to provide accurate diagnostic information while minimizing patient discomfort and recovery time.

The market encompasses a range of innovative medical procedures that enable physicians to obtain tissue samples for analysis through minimally invasive approaches, such as fine needle aspiration, core needle biopsy, and endoscopic biopsy. The driving forces behind the market's expansion include the growing prevalence of cancer and other chronic diseases, an increasing emphasis on early and accurate diagnosis, and the rising demand for less invasive medical procedures. Moreover, the market is benefiting from ongoing technological innovations that enhance these biopsy

techniques' precision, safety, and efficiency.

Innovation is pivotal in shaping the landscape of minimally invasive biopsy techniques in India. Advancements in imaging technologies, such as ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI), have enabled clinicians to accurately guide biopsy needles to target areas, ensuring the collection of high-quality tissue samples.

Additionally, integrating robotics and real-time image guidance systems has further improved these procedures' precision and success rates. These innovations enhance diagnostic accuracy and reduce procedural risks and patient discomfort. The growing adoption of such innovative techniques underscores the market's potential for continued growth, as healthcare providers and patients alike recognize the value of early and less invasive diagnostic approaches in improving patient outcomes and overall quality of care. For instance, Guardant Health's extensive liquid biopsy assay, Guardant360, swiftly and precisely informs treatment choices for individuals grappling with late-stage cancer, offering a dependable resource for guiding therapeutic decisions.

Advancements in Technology

India minimally invasive biopsy techniques market has seen significant advancements in technology in recent years. One such advancement is the development of image-guided biopsy techniques, which use imaging technologies such as ultrasound, CT scans, or MRI to accurately guide the biopsy needle to the target tissue. This technology has improved the accuracy and safety of biopsies, reducing the risk of damaging surrounding tissues and organs.

Another significant advancement is the development of liquid biopsy techniques, which detect biomarkers in body fluids such as blood, urine, or saliva, rather than requiring a tissue sample. The technique is less invasive and can monitor disease progression or treatment response. These technological advancements are expected to drive the growth of the Indian minimally invasive biopsy techniques market in the coming years. For example, in 2023, state-of-the-art technologies have transformed the landscape of cancer care in India. Concurrently, the escalating cancer burden in the country has spurred the development of novel technologies aimed at enhancing the diagnosis, treatment, and overall care of cancer patients.

For instance, in 2022, in a groundbreaking achievement, PGI Chandigarh has pioneered a liquid biopsy method for the early detection of oral cancer. This innovative

technique holds the potential to revolutionize cancer diagnosis by analyzing bodily fluids for cancer indicators, enabling swift and non-invasive identification. The development marks a significant step forward in improving oral cancer management, offering hope for more effective treatments and better patient outcomes.

Increased Awareness About Cancer

India minimally invasive biopsy techniques market is witnessing a surge in awareness about cancer, propelling its growth. With a growing understanding of the significance of early detection and accurate diagnosis, individuals have a heightened awareness about the necessity for effective cancer screening methods. The awareness surge is driving patients and healthcare providers towards minimally invasive biopsy techniques, such as fine needle aspiration, core needle biopsy, and endoscopic biopsies. These procedures offer reduced patient discomfort, faster recovery times, and precise tissue sampling, aligning well with the evolving preferences of informed patients. As awareness continues to spread, the market for minimally invasive biopsy techniques is poised for expansion, playing a pivotal role in improving cancer outcomes through early and accurate diagnosis.

Increasing Healthcare Spending for Market to Grow

India's healthcare spending has been increasing in recent years, which is expected to positively impact the minimally invasive biopsy techniques market. The growing burden of chronic diseases and the increasing demand for early and accurate diagnosis has increased healthcare spending, including diagnostic and therapeutic procedures such as biopsies. The government has been investing in the healthcare sector, with initiatives such as the Ayushman Bharat scheme aimed at providing healthcare coverage to the underprivileged population.

Private players are investing in the sector, with many hospitals and diagnostic centers upgrading their infrastructure to offer advanced minimally invasive biopsy techniques. Additionally, the growing medical tourism industry in India has increased demand for minimally invasive procedures. As a result, the increasing healthcare spending in India is expected to drive the growth of the country's minimally invasive biopsy techniques market. For example, in 2023, Static Droplet Microfluidic device was introduced. The innovation has the ability to rapidly detect circulating tumor cells that are released from primary tumors and flow within the bloodstream. The device plays a crucial role in enhancing cancer diagnosis and monitoring, playing a pivotal role in early detection, and facilitating adjustments in treatment strategies. By swiftly identifying these cells, it

provides healthcare with vital information about the advancement of the disease, opening doors to more precise interventions that could ultimately enhance patient outcomes.

Impact of COVID-19

The pandemic significantly impacted the India minimally invasive biopsy techniques market. The market witnessed a decline in growth due to the disruption of supply chains and the slowdown in the healthcare industry. The implementation of lockdowns and restrictions on elective surgeries further affected the demand for minimally invasive biopsy procedures. However, with the gradual ease of restrictions and the increasing awareness among patients about the benefits of early cancer diagnosis, the market has shown recovery and is expected to grow in the coming years. The adoption of telemedicine and other digital technologies in healthcare has facilitated the delivery of minimally invasive biopsy services to facilitate market growth.

Key Player Landscape and Outlook

India minimally invasive biopsy techniques market is expected to experience significant growth in the coming years. Companies have been investing heavily in research and development to innovate and improve their product offerings, while expanding their distribution networks to reach a wider customer base. The increasing prevalence of cancer and other chronic diseases and the growing awareness and adoption of minimally invasive procedures are expected to be major rivers of growth in the market. However, regulatory challenges and excessive costs associated with these techniques may somewhat hinder market growth. For example, in 2022, artificial intelligence technologies like 'Niramai,' 'iBreastExam,' and 'MammoAssist' emerged as beacons of hope for early detection through screening in resource-constrained environments. The advancements have the potential to enhance the quality of life for individuals battling breast cancer by facilitating timely identification, thus enabling better outcomes for patients.

Contents

1. RESEARCH METHODOLOGY

2. PROJECT SCOPE & DEFINITIONS

3. IMPACT OF COVID-19 ON INDIA MINIMALLY INVASIVE BIOPSY TECHNIQUES MARKET

4. EXECUTIVE SUMMARY

5. INDIA MINIMALLY INVASIVE BIOPSY TECHNIQUES MARKET OUTLOOK, FY2017-FY2031

5.1. Market Size & Forecast

5.1.1. By Value

5.1.2. By Volume

5.2. By Product Offered

5.2.1. Tests

5.2.2. Kits & Consumables

5.2.3. Instruments

5.3. By Technique

5.3.1. Liquid Biopsy

5.3.2. Optical Biopsy

5.3.3. Brush Biopsy

5.3.4. Pigmented Lesion Assays

5.3.5. Others (Breath Biopsy)

5.4. By Circulating Biomarker

5.4.1. Circulating Tumor Cells (CTCs)

5.4.2. Cell Free DNA (cfDNA)

5.4.3. Circulating Tumor DNA (ctDNA)

5.4.4. Extracellular Vesicles

5.4.5. Others (miRNA, CTECs, circRNA)

5.5. By Application

5.5.1. Clinical

5.5.1.1. Treatment Monitoring

5.5.1.2. Prognosis & Recurrence Monitoring

5.5.1.3. Treatment Selection

5.5.1.4. Others (Diagnosis & Screening)

5.5.2. Therapeutic

5.5.2.1. Lung Cancer

5.5.2.2. Breast Cancer

5.5.2.3. Prostate Cancer

5.5.2.4. Colorectal Cancer

5.5.2.5. Others (Blood Cancer, Thyroid Cancer)

5.6. By End-user

5.6.1. Hospitals & Clinics

5.6.2. Academic & Research Institutions

5.6.3. Ambulatory Care Centers

5.7. By Region

5.7.1. North

5.7.2. South

5.7.3. East

5.7.4. West & Central

5.8. By Company Market Share (%), FY2023

6. MARKET MAPPING, FY2023

6.1. By Product Offered

6.2. By Technique

6.3. By Circulating Biomarker

6.4. By Application

6.5. By End-user

6.6. By Region

7. MACRO ENVIRONMENT AND INDUSTRY STRUCTURE

7.1. Supply Demand Analysis

7.2. Import Export Analysis

7.3. Value Chain Analysis

7.4. PESTEL Analysis

7.4.1. Political Factors

7.4.2. Economic System

7.4.3. Social Implications

7.4.4. Technological Advancements

7.4.5. Environmental Impacts

7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)

7.5. Porter's Five Forces Analysis

- 7.5.1. Supplier Power
- 7.5.2. Buyer Power
- 7.5.3. Substitution Threat
- 7.5.4. Threat from New Entrant
- 7.5.5. Competitive Rivalry

8. MARKET DYNAMICS

- 8.1. Growth Drivers
- 8.2. Growth Inhibitors (Challenges and Restraints)

9. KEY PLAYERS LANDSCAPE

- 9.1. Competition Matrix of Top Five Market Leaders
- 9.2. Market Revenue Analysis of Top Five Market Leaders (in %, FY2023)
- 9.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
- 9.4. SWOT Analysis (For Five Market Players)
- 9.5. Patent Analysis (If Applicable)

10. PRICING ANALYSIS

11. CASE STUDIES

12. KEY PLAYERS OUTLOOK

- 12.1. Medtronic plc
 - 12.1.1. Company Details
 - 12.1.2. Key Management Personnel
 - 12.1.3. Products & Services
 - 12.1.4. Key Market Focus & Geographical Presence
 - 12.1.5. Financials (As Reported)
 - 12.1.6. Recent Developments
- 13.2. Roche Molecular Systems, Inc.
- 13.3. Boston Scientific India Private Limited
- 13.4. Beckman Coulter, Inc.
- 13.5. Bio-Rad Laboratories, Inc.
- 13.6. QIAGEN N.V.
- 13.7. Thermo Fisher Scientific India Private Limited.
- 13.8. Illumina India Biotechnology Private Limited

13.9. Agilent Technologies India Pvt. Ltd.

13.10. Olympus Medical Systems India Pvt Ltd.

*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

14. STRATEGIC RECOMMENDATIONS

15. ABOUT US & DISCLAIMER

I would like to order

Product name: India Minimally Invasive Biopsy Techniques Market Assessment, By Product Offered [Tests, Kits & Consumables, Instruments], By Technique [Liquid Biopsy, Optical Biopsy, Brush Biopsy, Pigmented Lesion Assays, Others], By Circulating Biomarker [Circulating Tumor Cells, Cell Free DNA, Circulating Tumor DNA, Extracellular Vesicles, Others], By Application [Clinical, Therapeutic], By End-user [Hospitals & Clinics, Academic & Research Institutions, Ambulatory Care Centers], By Region, Opportunities and Forecast, FY2017-FY2031F

Product link: <https://marketpublishers.com/r/IE6A30706E8CEN.html>

Price: US\$ 3,300.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/IE6A30706E8CEN.html>